Avelumab (AVE), cetuximab (CET) and irinotecan (IRI) for treatment refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): Translational analyses of the AVETUXIRI phase II trial

被引：0
|
作者：
Huyghe, N. [1 ]
Benidovskaya, E. [1 ]
Masoodi, T. [2 ]
Carrasco, J. [3 ]
De Cuyper, A. [4 ]
Sinapi, I. [3 ]
Vempalli, F. [2 ]
Verstraelen, E. [5 ]
Goffette, P. [5 ]
Ghaye, B. [5 ]
Papier, M.
Bedognetti, D. [2 ]
van Maanen, A. [5 ]
Castella, M-L. [5 ]
Galon, J. [6 ]
van den Eynde, M. [4 ]
机构：
[1] UCLouvain Univ Catholique Louvain, IIREC MIRO ONCO, Woluwe St Lambert, Belgium
[2] Sidra Med & Res Ctr, Al Rayyan, Qatar
[3] GHdC Grand Hop Charleroi Site Notre Dame, Med Oncol Dept, Charleroi, Belgium
[4] Clin Univ St Luc UCLouvain St Luc, Digest Oncol Dept, Woluwe St Lambert, Belgium
[5] Inst Roi Albert II Clin Univ St Luc, St Luc, Brussels, Belgium
[6] Cordeliers Res Ctr, Lab Integrat Canc Immunol, INSERM Team 15, Paris, France
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1265
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2237P
引用
收藏
页码：S1152 / S1152
页数：1
相关论文
共 50 条
  • [31] Randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer.
    Saltz, LB
    Lenz, HJ
    Hochster, H
    Wadler, S
    Hoff, P
    Kemeny, N
    Hollywood, E
    Gonen, M
    Wetherbee, S
    Chen, H
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 248S - 248S
  • [32] A phase II study of cetuximab (Erbitux®) plus FOLFIRI for irinotecan and oxaliplatin-refractory metastatic colorectal cancer
    Koo, Dong Hoe
    Lee, Jae-Lyun
    Kim, Tae Won
    Chang, Heung Moon
    Ryu, Min-Hoe
    Lee, Sung Sook
    Kim, Min Kyoung
    Sym, Sun Jin
    Lee, Jung Shin
    Kang, Yoon-Koo
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2007, 22 : S98 - S103
  • [33] Cetuximab plus irinotecan for metastatic colorectal cancer (mCRC): Safety analysis of 800 patients in a randomized phase III trial (EPIC).
    Abubakr, Y.
    Eng, C.
    Wong, L.
    Pautret, V.
    Scheithauer, W.
    Maurel, J.
    Kroening, H.
    Lutz, M.
    Zubel, A.
    Sobrero, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 160S - 160S
  • [34] Avelumab plus cetuximab in pre-treated RAS wild type metastatic colorectal cancer patients as a rechallenge strategy: The phase II CAVE (cetuximab-avelumab) mCRC study
    Martinelli, E.
    Martini, G.
    Troiani, T.
    Pietrantonio, F.
    Avallone, A.
    Normanno, N.
    Nappi, A.
    Maiello, E.
    Falcone, A.
    Santabarbara, G.
    Pinto, C.
    Santini, D.
    Ciardiello, D.
    Terminiello, M.
    Borrelli, C.
    Napolitano, S.
    Renato, D.
    Famiglietti, V.
    Esposito, L.
    Ciardiello, F.
    ANNALS OF ONCOLOGY, 2020, 31 : S409 - S410
  • [35] Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC): The phase II AVETUX-CRC trial (AIO KRK 0216).
    Stein, Alexander
    Binder, Mascha
    Bokemeyer, Carsten
    Al Batran, Salah Eddin
    Hinke, Axel
    Hegewisch-Becker, Susanna
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [36] Phase II study of biweekly cetuximab (C) and irinotecan (I) as a second-line regimen for metastatic colorectal cancer (mCRC)
    Carneiro, B. A.
    Bahary, N.
    Lembersky, B.
    Fakih, M.
    Krishnamurthi, S. S.
    Lancaster, S.
    Pinkerton, R.
    Crandall, T.
    Potter, D.
    Ramanathan, R. K.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [37] A phase II trial of metformin and fluorouracil (MetFU) for patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard treatment
    Miranda, Vanessa Costa
    Faria, Luiza Dib
    Freitas Melro Braghiroli, Maria Ignez
    Jacobs, Monica
    Sabbaga, Jorge
    Hoff, Paulo Marcelo
    Riechelmann, Rachel Pimenta
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [38] Results of a phase II study evaluating trifluridine/tipiracil plus nivolumab in patients with heavily pretreated microsatellite-stable (MSS) metastatic colorectal cancer (mCRC).
    Patel, Manish R.
    Falchook, Gerald Steven
    Hamada, Kensuke
    Makris, Lukas
    Winkler, Robert E.
    Gordon, Gilad Shalag
    Bendell, Johanna C.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
  • [39] A phase II study of durvalumab (MEDI4736) (anti-PDL1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC)
    Johnson, Benny
    Thomas, Jane V.
    Dasari, Arvind
    Raghav, Kanwal Pratap Singh
    Sanchez, Eduardo Vilar
    Kee, Bryan K.
    Eng, Cathy
    Parseghian, Christine Megerdichian
    Morris, Van K.
    Wolff, Robert A.
    Shureiqi, Imad
    Kopetz, Scott
    Overman, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [40] Tislelizumab plus cetuximab and irinotecan in refractory microsatellite stable and RAS wild-type metastatic colorectal cancer: a single-arm phase 2 study
    Xu, Xiaojing
    Ai, Luoyan
    Hu, Keshu
    Liang, Li
    Lv, Minzhi
    Wang, Yan
    Cui, Yuehong
    Li, Wei
    Li, Qian
    Yu, Shan
    Feng, Yi
    Liu, Qing
    Yang, Ying
    Zhang, Jiao
    Xu, Fei
    Yu, Yiyi
    Liu, Tianshu
    NATURE COMMUNICATIONS, 2024, 15 (01)
12345